Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
Stock Information for Fortress Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.